Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04472650
Registration number
NCT04472650
Ethics application status
Date submitted
14/07/2020
Date registered
15/07/2020
Date last updated
27/12/2021
Titles & IDs
Public title
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults
Query!
Scientific title
A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects
Query!
Secondary ID [1]
0
0
BGB-Sitravatinib-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Tumor
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Sitravatinib
Treatment: Drugs - Sitravatinib
Experimental: Dosing Sequence 1: Sitravatinib Free Base then Malate Salt - Sitravatinib free base capsule 120 mg on Day 1 in Period 1 then sitravatinib malate salt capsule 100 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
Experimental: Dosing Sequence 2: Sitravatinib Malate Salt then Free Base - Sitravatinib malate salt capsule 100 mg on Day 1 in Period 1 then sitravatinib free base capsule 120 mg on Day 1 in Period 2, with a minimum washout period between dose administrations of 14 days
Treatment: Drugs: Sitravatinib
Administered orally as a free base capsule
Treatment: Drugs: Sitravatinib
Administered orally as a malate salt capsule
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-8) of Sitravatinib
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [2]
0
0
Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC0-t) of Sitravatinib
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [3]
0
0
Maximum Observed Plasma Concentration (Cmax) of Sitravatinib
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [4]
0
0
Time of the Maximum Observed Plasma Concentration (Tmax) of Sitravatinib
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [5]
0
0
Apparent Terminal Elimination Half-life (T1/2) of Sitravatinib
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [6]
0
0
Apparent Total Plasma Clearance (CL/F) of Sitravatinib
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Primary outcome [7]
0
0
Apparent Volume of Distribution (Vz/F) of Sitravatinib
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Predose and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 and 168 hours postdose in each study period
Query!
Secondary outcome [1]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [1]
0
0
Adverse events (AEs) and serious adverse events are defined as an AE that starts during or after the first dose, or starts prior to the first dose and increases in severity after the first dose, including vital signs, physical examination, electrocardiogram, and laboratory parameters
Query!
Timepoint [1]
0
0
Up to Week 8
Query!
Eligibility
Key inclusion criteria
Key
1. Body mass index between 18.0 and 32.0 kg/m2, inclusive.
2. In good health, determined by no clinically significant findings from medical history,
physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory
evaluations at Screening and/or Check-in as assessed by the Investigator (or
designee).
3. Able to swallow multiple capsules.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. History of stomach or intestinal surgery or resection
2. Have previously completed or withdrawn from this study or any other study
investigating sitravatinib and have previously received the investigational product.
3. Participants who, in the opinion of the Investigator (or designee), should not
participate in this study.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/07/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/11/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
26
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
0
0
Linear Clinical Research Pty Lt(LCR) - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
6009 - Nedlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
BeiGene
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study was to investigate the relative bioavailability and
pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations
following oral administration in healthy adults.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04472650
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
BeiGene
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04472650
Download to PDF